GIM
PTGX icon

Glenmede Investment Management’s Protagonist Therapeutics PTGX Stock Holding History

Glenmede Investment Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.2M Sell
18,000
-3,434
-16% -$195K 0.01% 663
2025
Q2 		$1.18M Buy
+21,434
New +$1.03M 0.01% 670

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Glenmede Investment Management's PTGX Position: Q3 2025 in Review

Glenmede Investment Management reduced its Protagonist Therapeutics (PTGX) stake by 16% in Q3 2025, selling an estimated $195K and leaving 18,000 shares worth $1.2M. The position accounts for 0.01% of the portfolio, ranked #663.

Glenmede Investment Management first reported a position in PTGX in Q2 2025 and has held it in 2 quarters since. 275 funds tracked by Wall St. Rank hold PTGX as of Q3 2025.

  • Glenmede Investment Management held 18,000 shares of Protagonist Therapeutics worth $1.2M as of Q3 2025.
  • Glenmede Investment Management sold 3,434 Protagonist Therapeutics shares in Q3 2025, an estimated $195K.
  • Protagonist Therapeutics made up 0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #663 holding.
  • Glenmede Investment Management first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.